Skip to content
value.today

Solid Biosciences Inc.: financial analysis

Ratios worked out from 10 fiscal years of Solid Biosciences Inc.'s statements, compared with 102 companies in Pharmaceutical.

Return on equity, 2025
-109.9%
Pharmaceutical: -0.9%

Solid Biosciences Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.0×Price to book 4.0× against Pharmaceutical's median of 3.2×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-22.1%Free cash flow is -22.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.99 vs -3.06Diluted EPS -1.99 in fiscal 2025 against -3.06 the year before (report's currency).
    • ✗Net income higher than five years earlier-$174 M-$174 M in fiscal 2025 against -$88 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$174 MNet income -$174 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-109.9%-109.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.1×Current ratio 6.14 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year114.4%Diluted shares up 114.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Net loss of $174 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$157 million.
  • The share count rose 114.4% in the year.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

2of 6(3 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Solid Biosciences Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Operating margin————-530.5%1.8%—
Net margin————-530.0%-1.5%—
Return on equity-109.9%-94.6%-56.8%-41.0%-42.4%-0.9%7%
Return on assets-82.8%-70.5%-45.2%-34.9%-35.8%-1.3%7%

Growth#

Solid Biosciences Inc.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth———-40.6%—7.3%—

Financial strength#

Solid Biosciences Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Current ratio6.14×5.20×8.93×9.76×9.43×1.98×91%
Equity share of assets77.4%72.8%76.7%81.3%89.6%47.3%90%

Cash#

Solid Biosciences Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$-157 M$-101 M$-96 M$-101 M$-79 M$8 M0%
Free cash flow margin————-580.3%6.0%—
Capital spending share of revenue———37.3%9.4%2.6%—

Shareholder returns#

Solid Biosciences Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count114.4%105.3%133.6%19.6%105.6%1.8%7%

Efficiency#

Solid Biosciences Inc.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover———0.03×0.07×0.55×—

How each figure is worked out#

Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Solid Biosciences Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Solid Biosciences Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Solid Biosciences Inc.